Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection

The emerging threat represented by SARS-CoV-2 variants, demands the development of therapies for better clinical management of COVID-19. MAD0004J08 is a potent Fc-engineered monoclonal antibody (mAb) able to neutralize in vitro all current SARS-CoV-2 variants of concern (VoCs) including the omicron...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanini, Simone, Milleri, Stefano, Andreano, Emanuele, Nosari, Sarah, Paciello, Ida, Piccini, Giulia, Gentili, Alessandra, Phogat, Adhuna, Hyseni, Inesa, Leonardi, Margherita, Torelli, Alessandro, Montomoli, Emanuele, Paolini, Andrea, Frosini, Andrea, Antinori, Andrea, Nicastri, Emanuele, Girardi, Enrico, Plazzi, Maria Maddalena, Ippolito, Giuseppe, Vaia, Francesco, Della Cioppa, Giovanni, Rappuoli, Rino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046195/
https://www.ncbi.nlm.nih.gov/pubmed/35477725
http://dx.doi.org/10.1038/s41467-022-29909-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046195/
https://www.ncbi.nlm.nih.gov/pubmed/35477725
http://dx.doi.org/10.1038/s41467-022-29909-x

Ejemplares similares